

Tissue Regenix Group plc
(‘Tissue Regenix’, the ‘Company’)

Statement re. Suspension

Tissue Regenix plc (AIM: TRX), the regenerative medical devices company, announces that it has requested the temporary suspension of trading on AIM of the Company's ordinary shares, which has taken place with immediate effect.

The temporary suspension will allow the new Senior Leadership Team to further consider the previously announced restatement of revenue numbers for the financial year ended 31 December 2024 ("FY24"), the impact this has on H125 adjusted EBITDA, and the cash-position and ongoing expected performance of the business. Until this further review takes place the Company is not in a position to clarify its financial position.

Strict financial controls are being implemented, and a comprehensive review of the Group's cost structure is already underway, targeting a 2m+ cost reduction.

The Board remain committed to ensuring the recovery of the business and delivering sustainable, long-term earnings growth for shareholders. Further announcements will be made in due course.

For more information:

Tissue Regenix Group plc
Jay LeCoque, Executive Chairman

www.tissueregenix.com
via Walbrook PR

Cavendish Capital Markets Limited (Nominated Adviser and Broker)

Geoff Nash/Giles Balleny/Edward Whitley
Nigel Birks - Life Science Specialist Sales
Harriet Ward - ECM

Tel: +44 (0) 20 7466 5000

Walbrook PR (Financial PR and IR)
Alice Woodings / Paul McManus

Tel: +44 (0)20 7933 8780 or TissueRegenix@walbrookpr.com
Mob: +44 (0)7407 804 654 / +44 (0)7980 541 893

The information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the Market Abuse Regulation 'MAR' EU no. 596/2014. Upon the publication of this announcement via the Regulatory Information Service 'RIS', this inside information is now considered to be in the public domain.

About Tissue Regenix (www.tissueregenix.com)

Tissue Regenix is a leading medical device company in regenerative medicine. The Company's patented decellularisation technology (dCELL®) removes DNA and other cellular material from animal and human soft tissue, leaving an acellular tissue scaffold not rejected by the patient's body that can be used to repair diseased or damaged body structures. Current applications address many crucial clinical needs in sports medicine, foot and ankle injuries and wound care.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@seg.com or visit www.ms.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

SRSFLFFSIELFFIE